Pediatric dermatologists versus AI bots: Evaluating the medical knowledge and diagnostic capabilities of ChatGPT.

This study evaluates the clinical accuracy of OpenAI's ChatGPT in pediatric dermatology by comparing its responses on multiple-choice and case-based questions to those of pediatric dermatologists. ChatGPT's versions 3.5 and 4.0 were tested against questions from the American Board of Dermatology and the "Photoquiz" section of Pediatric Dermatology. Results show that human pediatric dermatology clinicians generally outperformed both ChatGPT iterations, though ChatGPT-4.0 demonstrated comparable performance in some areas. The study highlights the potential of AI tools in aiding clinicians with medical knowledge and decision-making, while also emphasizing the need for continual advancements and clinician oversight in using such technologies.

Effects of microbiome-based interventions on neurodegenerative diseases: a systematic review and meta-analysis.

Neurodegenerative diseases (NDDs) are characterized by neuronal damage and progressive loss of neuron function. Microbiome-based interventions, such as dietary interventions, biotics, and fecal microbiome transplant, have been proposed as a novel approach to managing symptoms and modulating disease progression. Emerging clinical trials have investigated the efficacy of interventions modulating the GM in alleviating or reversing disease progression, yet no comprehensive synthesis have been done. A systematic review of the literature was therefore conducted to investigate the efficacy of microbiome-modulating methods. The search yielded 4051 articles, with 15 clinical trials included. The overall risk of bias was moderate in most studies. Most microbiome-modulating interventions changed the GM composition. Despite inconsistent changes in GM composition, the meta-analysis showed that microbiome-modulating interventions improved disease burden (SMD, - 0.57; 95% CI - 0.93 to - 0.21; I2 = 42%; P = 0.002) with a qualitative trend of improvement in constipation. However, current studies have high methodological heterogeneity and small sample sizes, requiring more well-designed and controlled studies to elucidate the complex linkage between microbiome, microbiome-modulating interventions, and NDDs.

Robust cone-mediated signaling persists late into rod photoreceptor degeneration.

Rod photoreceptor degeneration causes deterioration in the morphology and physiology of cone photoreceptors along with changes in retinal circuits. These changes could diminish visual signaling at cone-mediated light levels, thereby limiting the efficacy of treatments such as gene therapy for rescuing normal, cone-mediated vision. However, the impact of progressive rod death on cone-mediated signaling remains unclear. To investigate the fidelity of retinal ganglion cell (RGC) signaling throughout disease progression, we used a mouse model of rod degeneration (Cngb1neo/neo). Despite clear deterioration of cone morphology with rod death, cone-mediated signaling among RGCs remained surprisingly robust: spatiotemporal receptive fields changed little and the mutual information between stimuli and spiking responses was relatively constant. This relative stability held until nearly all rods had died and cones had completely lost well-formed outer segments. Interestingly, RGC information rates were higher and more stable for natural movies than checkerboard noise as degeneration progressed. The main change in RGC responses with photoreceptor degeneration was a decrease in response gain. These results suggest that gene therapies for rod degenerative diseases are likely to prolong cone-mediated vision even if there are changes to cone morphology and density.

Our sense of sight depends on the retina, a thin layer of cells at the back of each eye. Its job is to detect light using cells called photoreceptors, then send that information to the rest of the brain. The retina has two kinds of photoreceptors: rods (active in dim light) and cones (which detect colour and work in bright light). We rely heavily on cone cells for vision in our daily lives. Retinitis pigmentosa is a progressive eye disease affecting photoreceptors. In the early stages of this disease, rods gradually die off. Next, cone cells start to die, inevitably resulting in blindness. There is currently no cure, although some experimental treatments are being developed that aim to prevent rod death or replace missing rod cells. However, it is unclear if these therapies will be effective, because we do not fully understand how rod death affects cone cells ­ for example, whether or not it damages the cones irreversibly. Scalabrino et al. therefore set out to track how the signals that cones send to the brain changed over time during progression of the disease using genetically altered mice that reproduced the symptoms of retinitis pigmentosa. In these mice, rod cells die off over several months, followed by complete loss of cones a few months later. Initial microscopy experiments looking at the shape and appearance of the cone cells revealed that the cones started looking abnormal long before all the rods died. Next, to determine if these unhealthy cones had stopped working, Scalabrino et al. measured the activity of the mice's retinal ganglion cells (RGCs) in bright light ­ in other words, when cones are normally active. RGCs transmit signals from photoreceptors to the brain, like a 'telephone line' between our brains and eyes. Applying a technique called information theory ­ which was originally used to determine how efficiently signals travel down telephone lines ­ to these experiments revealed that the RGCs still sent high-quality visual information from the cones to the brain. This is was surprising because the cones appeared to be dying and were surrounded by dead rods. This study sheds new light on the biological processes underpinning a devastating eye disease. The results suggest that treatments to restore vision could work even if given after a patient's cones start looking unhealthy, giving hope for the development of new therapies.